Phase III study designed to assess lapatinib in combination with chemotherapy for advanced HER2-positive gastric cancer in 2013 failed to meet the primary endpoint of improved overall survival (OS) against chemotherapy alone.
Phase III trial evaluating lapatinib combined with chemotherapy for advanced HER2-positive gastric cancer in 2013 failed to demonstrate a significant improvement in overall survival (OS) compared to chemotherapy alone.